Cover Image
市場調查報告書

急性疼痛:開發平台分析

Acute Pain - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232846
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
急性疼痛:開發平台分析 Acute Pain - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 194 Pages
簡介

所謂的急性疼痛,是指突然、急速、厲害的疼痛來襲。疼痛的時間雖然短,但是心跳變快,也導致不安神經症,呼吸變快,血壓上升,瞳孔擴大,流汗。是很難適當診斷和治療的疾病。症狀呈現與發炎、組織損傷、疾病過程、外科手術、生產等有關。急性疼痛襲擊身體的所有部位,一般為頭、背、腹部、胸部等。疼痛使用非類固醇的抗發炎劑(NSAIDs)等止痛藥緩和。

本報告提供急性止痛藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

急性疼痛 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AcelRx Pharmaceuticals, Inc.
  • Adynxx, Inc.
  • Amorsa Therapeutics Inc.
  • AnaBios Corporation
  • Anavex Life Sciences Corp.
  • AngioChem Inc.
  • Antibe Therapeutics, Inc.
  • AskAt Inc.
  • Cara Therapeutics, Inc.
  • Centrexion Corporation
  • Charleston Laboratories, Inc.
  • ChironWells GmbH
  • Cytogel Pharma, LLC
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH
  • Iroko Pharmaceuticals, LLC
  • KemPharm, Inc.
  • Kineta, Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Mallinckrodt Plc
  • MEDRx Co., Ltd.
  • Nanomerics Ltd
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Nuvo Research Inc.
  • Orbis Biosciences, Inc.
  • Orexo AB
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Recro Pharma, Inc.
  • Shulov Innovative Science Ltd.
  • Sigma-Tau S.p.A.
  • Syntrix Biosystems, Inc.
  • Thar Pharmaceuticals, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Trevena, Inc.
  • Yungjin Pharm. Co., Ltd.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (acetaminophen + benzhydrocodone hydrochloride) IR
  • (acetaminophen + hydrocodone bitartarate) ER
  • (acetaminophen + tramadol hydrochloride) SR
  • (buprenorphine hydrochloride + naloxone hydrochloride)
  • (celecoxib + tramadol hydrochloride)
  • (dexketoprofen + tramadol hydrochloride)
  • (etodolac + lidocaine)
  • AAT-076
  • alfentanil hydrochloride
  • AMS-410 FA
  • ANAVEX-1037
  • ANAVEX-1066
  • ANAVEX-1067
  • ANAVEX-1079
  • ANAVEX-1519
  • ANG-2002
  • ARX-04
  • ATB-352
  • AYX-1
  • BBI-11008
  • celecoxib
  • CL-108
  • CLH-10
  • CLH-5
  • CR-4056
  • CR-845
  • Cyt-1010
  • dexisometheptene mucate
  • dexmedetomidine hydrochloride
  • DF-2593A
  • E-52862
  • ECP-1014
  • ET-1
  • FY-101C
  • FY-103B
  • grapiprant
  • HS-731
  • ibuprofen
  • ibuprofen
  • ibuprofen
  • ketamine hydrochloride
  • lidocaine hydrochloride
  • meloxicam
  • meloxicam ER
  • 急性疼痛、慢性胰炎的疼痛用TGF-Beta-1抑制單株抗體
  • NKTR-195
  • NM-0127
  • oliceridine
  • Omnitram
  • 疼痛、搔癢用TRPV1標的肽
  • prednisone
  • 攝護腺酸性磷酸酉每
  • RO-656570
  • 疼痛用Nav1.9通道阻斷劑
  • 疼痛用Nav 1.7阻斷劑
  • 疼痛用Nav 1.8阻斷劑
  • ST-4070
  • T-109
  • tapentadol hydrochloride IR
  • TRV-734
  • U-2902
  • VPX-595
  • ZEP-3

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8346IDB

Summary

Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2016', provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Pain
  • The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
  • The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Pain Overview
  • Therapeutics Development
    • Pipeline Products for Acute Pain - Overview
    • Pipeline Products for Acute Pain - Comparative Analysis
  • Acute Pain - Therapeutics under Development by Companies
  • Acute Pain - Therapeutics under Investigation by Universities/Institutes
  • Acute Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Acute Pain - Products under Development by Companies
  • Acute Pain - Products under Investigation by Universities/Institutes
  • Acute Pain - Companies Involved in Therapeutics Development
    • AcelRx Pharmaceuticals, Inc.
    • Adynxx, Inc.
    • Amorsa Therapeutics Inc.
    • AnaBios Corporation
    • Anavex Life Sciences Corp.
    • AngioChem Inc.
    • Antibe Therapeutics, Inc.
    • AskAt Inc.
    • Cara Therapeutics, Inc.
    • Centrexion Therapeutics Corp
    • Charleston Laboratories, Inc.
    • ChironWells GmbH
    • Crescita Therapeutics Inc.
    • Cytogel Pharma, LLC
    • Dompe Farmaceutici S.p.A.
    • Grunenthal GmbH
    • Iroko Pharmaceuticals, LLC
    • KemPharm, Inc.
    • KPI Therapeutics, Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Mallinckrodt Plc
    • Nanomerics Ltd
    • Nanotherapeutics, Inc.
    • Orbis Biosciences Inc
    • Orexo AB
    • Orion Oyj
    • Pacira Pharmaceuticals, Inc.
    • Phosphagenics Limited
    • Recro Pharma, Inc.
    • Scilex Pharmaceuticals, Inc.
    • Shulov Innovative Science Ltd.
    • Syntrix Biosystems, Inc.
    • Thar Pharmaceuticals, Inc.
    • Trevena, Inc.
    • Yungjin Pharm. Co., Ltd.
  • Acute Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile
    • (acetaminophen + hydrocodone bitartarate) ER - Drug Profile
    • (acetaminophen + tramadol hydrochloride) SR - Drug Profile
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
    • (celecoxib + tramadol hydrochloride) - Drug Profile
    • AAT-076 - Drug Profile
    • alfentanil hydrochloride - Drug Profile
    • AMS-410 FA - Drug Profile
    • ANAVEX-1037 - Drug Profile
    • ANAVEX-1066 - Drug Profile
    • ANAVEX-1067 - Drug Profile
    • ANAVEX-1079 - Drug Profile
    • ANAVEX-1519 - Drug Profile
    • ANG-2002 - Drug Profile
    • ARX-04 - Drug Profile
    • ATB-352 - Drug Profile
    • AYX-1 - Drug Profile
    • BBI-11008 - Drug Profile
    • celecoxib - Drug Profile
    • CL-108 - Drug Profile
    • CR-4056 - Drug Profile
    • Cyt-1010 - Drug Profile
    • dexmedetomidine hydrochloride - Drug Profile
    • DF-2593A - Drug Profile
    • difelikefalin - Drug Profile
    • Drug for Acute Pain - Drug Profile
    • ECP-1014 - Drug Profile
    • ET-1 - Drug Profile
    • FY-101C - Drug Profile
    • FY-103B - Drug Profile
    • grapiprant - Drug Profile
    • HPI-201 - Drug Profile
    • HS-731 - Drug Profile
    • ibuprofen - Drug Profile
    • ibuprofen - Drug Profile
    • ibuprofen - Drug Profile
    • ketamine hydrochloride - Drug Profile
    • lidocaine hydrochloride - Drug Profile
    • meloxicam - Drug Profile
    • meloxicam - Drug Profile
    • meloxicam ER - Drug Profile
    • Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
    • MR-309 - Drug Profile
    • NM-0127 - Drug Profile
    • oliceridine - Drug Profile
    • Omnitram - Drug Profile
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
    • prednisone - Drug Profile
    • Prostatic Acid Phosphatase - Drug Profile
    • RO-656570 - Drug Profile
    • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
    • Small Molecules to Block Nav 1.7 for Pain - Drug Profile
    • Small Molecules to Block Nav 1.8 for Pain - Drug Profile
    • Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile
    • T-109 - Drug Profile
    • tapentadol hydrochloride - Drug Profile
    • TRV-734 - Drug Profile
    • U-2902 - Drug Profile
    • VPX-595 - Drug Profile
    • ZEP-3 - Drug Profile
  • Acute Pain - Dormant Projects
  • Acute Pain - Discontinued Products
  • Acute Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Pain, H2 2016
  • Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016
  • Acute Pain - Pipeline by Adynxx, Inc., H2 2016
  • Acute Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Acute Pain - Pipeline by AnaBios Corporation, H2 2016
  • Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Acute Pain - Pipeline by AngioChem Inc., H2 2016
  • Acute Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016
  • Acute Pain - Pipeline by AskAt Inc., H2 2016
  • Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Acute Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
  • Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2016
  • Acute Pain - Pipeline by ChironWells GmbH, H2 2016
  • Acute Pain - Pipeline by Crescita Therapeutics Inc., H2 2016
  • Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
  • Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Acute Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016
  • Acute Pain - Pipeline by KemPharm, Inc., H2 2016
  • Acute Pain - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Acute Pain - Pipeline by Mallinckrodt Plc, H2 2016
  • Acute Pain - Pipeline by Nanomerics Ltd, H2 2016
  • Acute Pain - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Acute Pain - Pipeline by Orbis Biosciences Inc, H2 2016
  • Acute Pain - Pipeline by Orexo AB, H2 2016
  • Acute Pain - Pipeline by Orion Oyj, H2 2016
  • Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
  • Acute Pain - Pipeline by Phosphagenics Limited, H2 2016
  • Acute Pain - Pipeline by Recro Pharma, Inc., H2 2016
  • Acute Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016
  • Acute Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016
  • Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016
  • Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2016
  • Acute Pain - Pipeline by Trevena, Inc., H2 2016
  • Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Pain - Dormant Projects, H2 2016
  • Acute Pain - Dormant Projects (Contd..1), H2 2016
  • Acute Pain - Dormant Projects (Contd..2), H2 2016
  • Acute Pain - Dormant Projects (Contd..3), H2 2016
  • Acute Pain - Dormant Projects (Contd..4), H2 2016
  • Acute Pain - Dormant Projects (Contd..5), H2 2016
  • Acute Pain - Dormant Projects (Contd..6), H2 2016
  • Acute Pain - Discontinued Products, H2 2016
  • Acute Pain - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Acute Pain, H2 2016
  • Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top